HL
SBIO icon

HeadInvest LLC’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

HeadInvest LLC’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$105 – 595
2023
Q3 		$105 Buy
+4
New +$120 ﹤0.01% 743

Other funds holding SBIO

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

HeadInvest LLC's SBIO Position: Q4 2023 in Review

HeadInvest LLC sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q4 2023, closing a stake of 4 shares — an estimated $105 sold.

HeadInvest LLC first reported a position in SBIO in Q3 2023 and held it in 1 quarter. The position peaked at $105 in Q3 2023. 34 funds tracked by Wall St. Rank hold SBIO as of Q4 2023.

  • HeadInvest LLC reported no remaining ALPS Medical Breakthroughs ETF position as of Q4 2023 after selling out during the quarter.
  • HeadInvest LLC sold 4 ALPS Medical Breakthroughs ETF shares in Q4 2023, an estimated $105.
  • HeadInvest LLC first reported a position in ALPS Medical Breakthroughs ETF in Q3 2023 and held it in 1 quarter.
  • HeadInvest LLC's ALPS Medical Breakthroughs ETF position peaked at $105 in Q3 2023.
  • 34 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.